Antibody Drug Conjugates, the beginning of the end?
Antibody Drug Conjugates Against Tumor Stroma: The Beginning of The End? by Mirella Zulueta, Business Development Director at Oncomatryx The potential of a technology trigger Despite many research breakthroughs over the last few decades, conventional cancer treatment strategies still face many limitations. Antibody-drug conjugates (ADCs) belong to a fairly new class of targeted cell … Leer más